Skip to main content
SpringerLink
Log in
Book cover

Manual of Heart Failure Management pp 1–15Cite as

Management of Hypertension in Heart Failure

  • Chapter
  • First Online:

  • 877 Accesses

Hypertension is the most common chronic medical disorder in the United States. According to JNC 7 criteria, more than 65 million Americans have hypertension and an additional 25% of the population has prehypertension. 1 Despite its vast prevalence, hypertension remains highly under recognized with a full 30% of patients unaware that they have the condition. In developed societies, blood pressure increases with age. Diastolic BP plateaus in the fifth decade and may decline thereafter but systolic BP continues to rise steadily through the seventh decade. The Framingham Heart Study estimated the 20-year risk of developing hypertension as >90% for normotensive men and women of middle age (55-65 years of age). 2 Among Americans over age 65, more than half have isolated systolic or combined systolic-diastolic hypertension.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Chobanian AV, Bakris GI, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    Article  PubMed  CAS  Google Scholar 

  2. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. J Am Med Assoc 2002; 287: 1003–1010.

    Article  Google Scholar 

  3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991; 265: 3255–3264.

    Article  Google Scholar 

  4. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761–2788.

    Article  PubMed  Google Scholar 

  5. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. J Am Med Assoc 1996; 275: 1557–1562.

    Article  CAS  Google Scholar 

  6. Forette F, Seux ML, Staessen JA, et al Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–1351.

    Article  PubMed  CAS  Google Scholar 

  7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

    Article  PubMed  Google Scholar 

  8. Sheps SG, Roccella EJ. Reflections on the sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Curr Hypertens Rep 1999; 1: 342–345.

    Article  PubMed  CAS  Google Scholar 

  9. Bonow, RO, Udelson, JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992; 117: 502.

    PubMed  CAS  Google Scholar 

  10. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955–1964.

    Article  PubMed  CAS  Google Scholar 

  11. O'Rorke JE, Richardson WS. Evidence based management of hypertension: What to do when blood pressure is difficult to control. Br Med J 2001; 322: 1229–1232.

    Article  Google Scholar 

  12. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544–549.

    PubMed  CAS  Google Scholar 

  13. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657–667.

    Article  Google Scholar 

  14. Sacks FM, Svetkey LP, Vollmer WM, et al Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3–10.

    Article  PubMed  CAS  Google Scholar 

  15. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136: 493–503.

    PubMed  Google Scholar 

  16. Specchia G, De Servi S, Scire A, Assandri J, Berzuini C, Angoli L, La Rovere MT, Cobelli F. Interaction between exercise training and ejection fraction in predicting prognosis after a first myocardial infarction. Circulation 1996; 94: 978–982.

    PubMed  CAS  Google Scholar 

  17. Wang JG, Staessen JA. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens (Greenwich) 2003; 5: 66–75.

    Article  CAS  Google Scholar 

  18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002; 288: 2981–2997.

    Article  Google Scholar 

  19. Dahlof B, Devereux RB, Kjeldsen SE, et al Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  PubMed  CAS  Google Scholar 

  20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study. N Engl J Med 2000; 342: 145–153.

    Article  PubMed  CAS  Google Scholar 

  21. Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003; 362: 782–788.

    Article  PubMed  CAS  Google Scholar 

  22. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293.

    Article  Google Scholar 

  23. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828.

    Google Scholar 

  24. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312–2318.

    PubMed  CAS  Google Scholar 

  25. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    Article  PubMed  CAS  Google Scholar 

  26. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.

    Article  PubMed  CAS  Google Scholar 

  27. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362: 772–776.

    Article  PubMed  CAS  Google Scholar 

  28. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–2007.

    Article  Google Scholar 

  29. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7–13.

    Article  PubMed  CAS  Google Scholar 

  30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Randomized Aldactone Evaluation Study Investigators (RALES). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.

    Article  PubMed  CAS  Google Scholar 

  31. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. (EPHESUS) N Engl J Med 2003; 348: 1309–1321.

    Article  CAS  Google Scholar 

  32. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial: Prospective randomized amlodipine survival evaluation. Am J Cardiol 1998; 82: 881–887.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine Cardiology Division, University of Rochester, Rochester, NY, USA

    Matthew R. Jonovich & John D. Bisognano

Authors
  1. Matthew R. Jonovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John D. Bisognano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew R. Jonovich .

Editor information

Editors and Affiliations

  1. Department of Medicine, Cardiology Division, University of Rochester, Rochester, NY, USA

    John D Bisognano MD, PhD , Mary Beth Earley CCRN, MS, NP  & Marc L Baker MD, PhD ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Jonovich, M.R., Bisognano, J.D. (2009). Management of Hypertension in Heart Failure. In: Bisognano, J.D., Earley, M.B., Baker, M.L. (eds) Manual of Heart Failure Management. Springer, London. https://doi.org/10.1007/978-1-84882-185-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-84882-185-9_1

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84882-184-2

  • Online ISBN: 978-1-84882-185-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation